A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND/OBJECTIVE: Weight loss in individuals with obesity offers metabolic benefits but may increase fracture risk, potentially influenced by the modality of weight loss. This study aimed to compare fracture risk in patients with obesity treated…
BACKGROUND: Cardiovascular diseases, overweight, type 2 diabetes and chronic kidney disease increase the risk of cardiovascular events.Glucagon-like peptide-1 analogues are recommended by the European Society of Cardiology and the American College of…
BACKGROUND: Obesity is a chronic disease with significant global health repercussions. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1RAs) are now established as evidence-based options for long-term obesity manageme…
INTRODUCTION: According to the Obesity Medicine Association, obesity is a chronic, progressive, relapsing, multifactorial and treatable neurobehavioral disease. A small number of drugs have been approved by the Food & Drug Administration (FDA) for we…
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated substantial efficacy in managing type 2 diabetes mellitus (T2DM). It provides glycemic control, promotes weight loss, and offers cardiovascular protection. Evidence a…
OBJECTIVE: This study aims to identify the risk factors associated with gastrointestinal adverse events induced by semaglutide in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive risk model. METHODS: A total of 215 patients w…
BACKGROUND: This study evaluated the impact of semaglutide on postoperative complications following total knee arthroplasty by body mass index (BMI) class. METHODS: A retrospective analysis of a national claims database was performed for patients und…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Ad…
Aneurysmal Subarachnoid Hemorrhage (SAH) is a devastating cerebrovascular event with high morbidity and mortality rates, and early brain injury following SAH (EBI-SAH) within 72 h leads to a poor prognosis. Despite advances in our understanding of th…
PURPOSE: Patients with type II diabetes mellitus are at greater risk of carpal tunnel syndrome and of complications following carpal tunnel release (CTR). Although recent orthopedic literature suggests preoperative semaglutide use may reduce complica…
OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown beneficial effects on clinical outcomes in patients with heart failure (HF) with preserved ejection fraction (HFpEF) or minimally reduced ejection fraction (HFmrEF). This ne…
BACKGROUND: It is unclear whether the time-varying mediation effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the three-point major adverse cardiovascular event (3P-MACE) outcomes, including nonfatal stroke, nonfatal myocardial infa…
Obesity is a chronic, multifactorial metabolic disease associated with various factors such as insulin resistance, increased adipogenesis, induction of gluconeogenesis, epigenetic mechanisms, chronic inflammatory state, and oxidative stress. Anti-obe…
OBJECTIVES: To identify novel targets to treat obesity, we focused on the equilibrative nucleoside transporter 1 (ENT1), which is a key regulator of extracellular adenosine levels in adipose tissue. Adenosine has been shown to control multiple aspect…
Obesity in non-diabetic adults remains a significant clinical challenge, prompting the need for effective pharmacological therapies that achieve meaningful weight loss with acceptable tolerability. Semaglutide, a selective glucagon-like peptide-1 (GL…
Erectile dysfunction (ED) is a common yet frequently underrecognized microvascular complication of diabetes, affecting up to three out of four individuals. Key contributing factors include advancing age, long-standing disease duration, and suboptimal…
Semaglutide is a once-weekly GLP-1 receptor agonist that has been proposed as a gerotherapeutic, yet no data exist on its effects on epigenetic aging. We therefore conducted a post-hoc epigenetic analysis of a 32-week, double-blind, placebo-controlle…
BACKGROUND: Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) frequently coexist, posing a significant challenge due to increased risks of cardiovascular disease and mortality. Glucagon-like peptide-1 receptor agonists, such as semaglu…